Emma Boys

Medical Oncologist | Clinical translation of proteomics PhD ProCan @CMRI_AUS

[Elizabeth McKenna @ElizSMcKenna]

Now online in @CD_AACR: Federated Deep Learning Enables Cancer Subtyping by Proteomics - by @zhaoxiang_cai, @EmmaBoys7, @imNoor_Z, @dradelaref1, Peter Hains, Phillip Robinson, Qing Zhong, @rreddel, and colleagues https://t.co/Y7lc5UN0Zt @CMRI_AUS

[Jia (Jenny) Liu MD PhD @JiaJennyLiu]

Congrats @CMRI_AUS PhD Student @EmmaBoys7: outcomes of contemporary CUP cohort from 3🇦🇺🏥 showing:
➡️Aggressive biology + extensive 🔬 = 57% got systemic Rx
➡️mPFS 6.8mo, mOS 10.2mo
➡️ @myESMO CUP prognostic in realworld setting
➡️Only 20% 🧬 profile
https://t.co/b37F53IB6t

[Liz Connolly @DrLizConnolly]

Lovely piece describing our #proteomic research programme at ProCan at @CMRI_AUS

Very proud to be part of this team doing #sarcoma proteomics 😊

@EmmaBoys7 @JiaJennyLiu @rreddel @dradelaref1 @ErinMHumphries @rebecca_poulos @ehurt01 @srithegreat143 @SydCancerPtnrs @Sydney_Uni

[Jia (Jenny) Liu MD PhD @JiaJennyLiu]

Super proud of Dr Emma Boys who was merit recipient at #ASCO23 and presented her research on a pan-cancer proteomics tissue of origin using #ProCan DIA mass spectrometry @CMRI_AUS.

[Jia (Jenny) Liu MD PhD @JiaJennyLiu]

Congrats to my PhD student @EmmaBoys7 Merit Award recipient at @ASCO #ASCO23, excited to be attending this year and sharing results from @CMRI_AUS ProCan on proteomics to improve cancer classification and prognosis! https://t.co/0THo8LAeOe

[Razelle Kurzrock, MD @Dr_R_Kurzrock]

Therapeutic impact of knowing the unknown— for cancer of unknown primary— multi-omic interrogation and matching tumors with drugs was associated with improved outcomes. Molecular Oncology 2022

[Arndt Vogel @ArndtVogel]

❗️Intrahepatic #cholangiocarcinoma hidden within cancer of unknown primary.
https://t.co/rRLYKKRUW0

👉34% of pts with liver-involved pCUP, fulfilled the radiological criteria for iCCA
👉Careful evaluation needed, incl. NGS ➡️don't miss🎯therapies

@myESMO

[Stefan Fröhling @StefanFrohling]

Please read our new paper on the clinical value of comprehensive molecular profiling in patients with cancer of unknown primary site. Another wonderful team effort of the @NCT_HD, @NCT_UCC_DD, @DKFZ, and @DKTK_ MASTER precision oncology network. https://t.co/yJrpZb3JHK